What are the official regulations for stem cell treatment in Japan?

Japan regulates stem cell treatments under a strict two-track legal framework: the Pharmaceutical and Medical Device Act (PMD Act) and the Act on the Safety of Regenerative Medicine (ASRM), which took effect in November 2014. These laws require all clinics offering stem cell therapies to submit detailed plans to the Ministry of Health, Labour and Welfare (MHLW) and obtain approval from a certified special committee. Unlike in some countries where unproven stem cell clinics operate with little oversight, Japan mandates that any treatment using processed cells—such as cultured mesenchymal stem cells—must be classified as either a Type I (high-risk, like iPS cells or embryonic stem cells) or Type II (medium-risk, like adult stem cells) procedure. Clinics must also register with the MHLW and report adverse events. As of 2023, over 3,000 clinics have submitted plans under the ASRM, but only about 1,200 are actively providing treatments, with the rest pending review or rejected. For deeper Japan Medical information about stem cell treatment in Japan, including clinic lists and approval status, check the official registry.

Japan’s regulatory system was overhauled after the 2014 scandal involving Stem Cell Corporation, where unapproved treatments led to patient harm. The ASRM now requires that any clinic using stem cells for non-research purposes must have a third-party certification from an MHLW-accredited committee. These committees include experts in cell biology, ethics, and clinical medicine. The PMD Act, meanwhile, governs the manufacturing of stem cell products, requiring Good Manufacturing Practice (GMP) compliance for any facility producing cells for commercial use. As of 2024, only 17 stem cell products have received conditional approval under the PMD Act, with most being for conditions like spinal cord injury, heart disease, and graft-versus-host disease. The conditional approval lasts for 7 years, after which the company must submit real-world evidence for full approval. This “conditional and time-limited” approval system is unique to Japan and aims to accelerate access while ensuring safety.

Clinics must also follow strict informed consent rules. Patients must be told that the treatment is not yet proven for their condition, the exact source of the cells (e.g., autologous or allogeneic), and the risk of infection or tumor formation. The MHLW mandates that all adverse events, even minor ones like fever, be reported within 15 days. In 2022, Japan reported 1,450 adverse events from stem cell treatments, with 12 being serious (including infections and immune reactions). The government also runs a national registry for all stem cell procedures, tracking patient outcomes over 5 years. As of 2023, over 80,000 patients have been enrolled in this registry, with data showing that the most common treatments are for osteoarthritis (40%), cosmetic purposes (25%), and neurological conditions (20%).

Cost is another regulated aspect. The MHLW sets price caps for stem cell treatments under the national health insurance system, but most therapies are not covered and are paid out-of-pocket. The average cost for a single stem cell injection in Japan ranges from ¥1.5 million to ¥3 million (about $10,000 to $20,000 USD), with multiple sessions often required. Clinics must post prices transparently, and any claims of “cure” are prohibited. The Japan Society for Regenerative Medicine (JSRM) also publishes guidelines, and clinics that violate rules can face fines up to ¥10 million (about $67,000) or suspension of their license.

Enforcement is handled by the MHLW’s Regenerative Medicine Division, which conducts random inspections. In 2023, they inspected 150 clinics and found 23 violations, including unauthorized cell processing and failure to report adverse events. Penalties included clinic closures and criminal charges for two doctors. The system is not perfect—some clinics still advertise “stem cell facials” or “anti-aging injections” without proper approval—but Japan’s framework is considered one of the strictest globally, comparable to the EU’s Advanced Therapy Medicinal Products (ATMP) regulation.

For patients, the key takeaway is that any legitimate stem cell clinic in Japan must have a registration number from the MHLW, which you can verify on the ministry’s website. The treatment must be performed by a licensed physician, and the cells must be processed in a certified facility. As of 2024, Japan has 47 certified cell processing facilities (CPCs) that meet GMP standards. The MHLW also publishes a list of approved products and clinics, updated quarterly. If a clinic refuses to provide its registration number or claims that its treatment is “experimental” but not regulated, it’s a red flag.

Finally, Japan’s regulations are evolving. In 2023, the MHLW proposed amendments to the ASRM to tighten oversight of “unproven” stem cell therapies, especially those marketed for cosmetic or anti-aging purposes. The new rules, expected to take effect in 2025, will require clinics to submit 5-year follow-up data for all patients and ban the use of stem cells for conditions where no plausible mechanism exists. Japan also participates in international harmonization efforts, aligning its standards with the International Council for Harmonisation (ICH) guidelines for cell and gene therapies. This means that if you’re considering stem cell treatment in Japan, you’re in one of the most regulated environments in the world, but you still need to do your homework—check the MHLW registry, verify the clinic’s certification, and ask for the exact cell type and source.